Hagens Berman reminds Corcept Therapeutics investors that the deadline to seek Lead Plaintiff status in the pending securities class action is April 21, 2026.

National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026.

The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights.

The lawsuit, Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al., No. 26-cv-01525, was filed in the U.S. District Court for the Northern District of California. The action seeks to recover losses for all persons and entities who purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025 (the "Class Period").

Investors in Corcept (CORT) are encouraged to visit the Hagens Berman's CORT Case Page to review the allegations: www.hbsslaw.com/cases/corcept  

"The heart of the Corcept case is a classic 'information gap' between what the company told the public and what the FDA was reportedly telling the company behind closed doors," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

Summary of the Allegations: The "Relacorilant" Disclosure Failure

The filed complaint in Allegheny County v. Corcept alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the company's lead drug candidate, relacorilant, by failing to disclose:

Concealed FDA Concerns: That during pre-submission meetings in 2024 and early 2025, the FDA warned Corcept on several occasions that its clinical data lacked sufficient evidence of effectiveness to support a New Drug Application (NDA).

Misleading Narrative: That defendants continued to tout Phase 3 results, despite knowing the FDA viewed the data as fundamentally flawed.

The CRL Bombshell: On December 31, 2025, Corcept revealed it had received a Complete Response Letter (CRL) from the FDA. The agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant due to an "insufficient" evidentiary record.

50% Market Crash: Following this disclosure, Corcept's stock price plummeted from $70.20 on December 30, 2025, to close at $34.80.06 on December 31, 2025—erasing nearly $2.5 billion in market capitalization in a single day.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_478962262/2227/2026-05-11T22:25:41